of Boston points out that the use of anti-VEGF therapy in the treatment of
patients with wet macular degeneration has revolutionized outcomes in this
disease. However, in light of the work of Dr. D'Amore and others, in
elucidating possible systemic and ocular side effects of these drugs,
"caution must be exercised in identifying patients at increased risk of
problems with long-term VEGF blockade, and potential side effects must be
detected early in the assessment of patients who will require repeated
dosages of anti-VEGF agents."
The study is also relevant to the drug Avastin, which was initially
approved for intravenous use as an anti-angiogenic agent in the treatment
of cancer, but is also widely used intravitreally for the treatment of wet
AMD because of its similar mode of action and much lower cost.
The next steps in D'Amore's research will include investigating the
specific functions of VEGF in the eye.
Authors of the study include: Magali Saint-Geniez (1,2), Arindel S. R.
Maharaj (1), Tony E. Walshe (1,2), Budd A. Tucker (1,2), Eiichi Sekiyama
(1,2), Tomoki Kurihara (1), Diane C. Darland (4), Michael J. Young (1,2),
Patricia A. D'Amore (1,2,3)
(1) Schepens Eye Research Institute
(2) Department of Ophthalmology, Harvard Medical School
(3) Department of Pathology, Harvard Medical School
(4) University of North Dakota, Grand Forks, North Dakota
Schepens Eye Research Institute is an affiliate of Harvard Medical
School and is the largest independent eye research institute in the nation.
Page: 1 2 3 Related medicine news :1
|SOURCE Schepens Eye Research Institute|
Copyright©2008 PR Newswire.
All rights reserved
. Tweens and teens double use of diabetes drugs2
. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs3
. Tests Could Predict Benefit From Cancer Drugs4
. Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known5
. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift6
. Common Heart Drugs May Hamper Blood Thinner7
. The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 20178
. Albertsons LLC Launches $4.99 Prescription Discount Program Covering Over 500 Generic Drugs9
. Existing anti-obesity drugs may be effective against flu, hepatitis and HIV10
. Cholesterol Drugs May Raise Post-Op Delirium Risk11
. First generation antipsychotic drugs as effective as newer ones in some children